Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Lanadelumab (Primary)
- Indications Lung injury
- Focus Adverse reactions
- 15 Apr 2024 Planned End Date changed from 1 Jun 2023 to 1 Dec 2024.
- 15 Apr 2024 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 15 Apr 2024 Status changed from recruiting to active, no longer recruiting.